ALGS - CIK 0001799448
Aligos Therapeutics, Inc. (ALGS) reported net income of -$24.19M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$24.19M | +81.6% |
| FY 2024 | -$131.21M | -49.6% |
| FY 2023 | -$87.68M | +8.7% |
| FY 2022 | -$96.05M | +25.2% |
| FY 2021 | -$128.33M | -18.2% |
| FY 2020 | -$108.54M | -107.7% |
| FY 2019 | -$52.26M | - |
Aligos Therapeutics, Inc. (ALGS) reported net income of -$24.19M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, Aligos Therapeutics, Inc.'s net income grew from -$52.26M to -$24.19M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.